Synthesis of bioengineered heparin chemically and biologically similar to porcine-derived products and convertible to low MW heparin
Open accessThe DOI matches its Crossref record; 67 of the 69 references it cites were found in a registry or an index.
Abstract
Heparins have been invaluable therapeutic anticoagulant polysaccharides for over a century, whether used as unfractionated heparin or as low molecular weight heparin (LMWH) derivatives. However, heparin production by extraction from animal tissues presents multiple challenges, including the risk of adulteration, contamination, prion and viral impurities, limited supply, insecure supply chain, and significant batch-to-batch variability. The use of animal-derived heparin also raises ethical and religious concerns, as well as carries the risk of transmitting zoonotic diseases. Chemoenzymatic synthesis of animal-free heparin products would offer several advantages, including reliable and scalable production processes, improved purity and consistency, and the ability to produce heparin polysaccharides with molecular weight, structural, and functional properties equivalent to those of the United States Pharmacopeia (USP) heparin, currently only sourced from porcine intestinal mucosa. We report a scalable process for the production of bioengineered heparin that is biologically and compositionally similar to USP heparin. This process relies on enzymes from the heparin biosynthetic pathway, immobilized on an inert support and requires a tailored N -sulfoheparosan with N -sulfo levels similar to those of porcine heparins. We also report the conversion of our bioengineered heparin into a LMWH that is biologically and compositionally similar to USP enoxaparin. Ultimately, we demonstrate major advances to a process to provide a potential clinical and sustainable alternative to porcine-derived heparin products.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For the endothelial cell cultures in our model, commonly used supplements like heparin, which is animal derived, can be replaced with biochemically synthesized alternatives (Douaisi et al., 2024).”
From Considering future qualification for regulatory science in the early development of microphysiological systems: a case study of microthrombosis in a Vessel-on-Chip (2024) · cites this paper as Douaisi et al., 2024
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Collins, R., Scrimgeour, A., Yusuf, S., & Peto, R. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805053181805 · Cited by 1,314
Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis
Vlodavsky, I., Friedmann, Y., Elkin, M., Aingorn, H., Atzmon, R., Ishai-Michaeli, R., Bitan, M., Pappo, O., Peretz, T., Michal, I., et al. (1999) · Nature Medicine · doi:10.1038/10518 · Cited by 803
Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events
Guerrini, M., Beccati, D., Shriver, Z., Naggi, A., Viswanathan, K., Bisio, A., Capila, I., Lansing, J. C., Guglieri, S., Fraser, B., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1407 · Cited by 628
Self-citationContaminated Heparin Associated with Adverse Clinical Events and Activation of the Contact System
Kishimoto, T. K., Viswanathan, K., Ganguly, T., Elankumaran, S., Smith, S., Pelzer, K., Lansing, J. C., Sriranganathan, N., Zhao, G., Galcheva-Gargova, Z., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0803200 · Cited by 621
Prandoni, P., Carta, M., Cogo, A., Ruol, A., Vigo, M., Casara, D., Lensing, A. W. A., Büller, H. R., & ten Cate, J. W. (1992) · The Lancet · doi:10.1016/0140-6736(92)91054-c · Cited by 583
THE THROMBOPLASTIC ACTION OF CEPHALIN
McLean, J. (1916) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1916.41.2.250 · Cited by 530
Conformation and dynamics of heparin and heparan sulfate
Mulloy, B., & Forster, M. J. (2000) · Glycobiology · doi:10.1093/glycob/10.11.1147 · Cited by 315
Protein Design: From the Aspect of Water Solubility and Stability
Qing, R., Hao, S., Smorodina, E., Jin, D., Zalevsky, A., & Zhang, S. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00757 · Cited by 312
Linhardt, R. J. (2016) · Frontiers in Bioscience · doi:10.2741/4462 · Cited by 232
Self-citationA proteoglycan form of heparin and its degradation to single-chain molecules.
Robinson, H. C., Horner, A. A., Höök, M., Ogren, S., & Lindahl, U. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37973-5 · Cited by 211
Contribution of EXT1, EXT2, and EXTL3 to Heparan Sulfate Chain Elongation
Busse, M., Feta, A., Presto, J., Wilén, M., Grønning, M., Kjellén, L., & Kusche-Gullberg, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703560200 · Cited by 211
Pinhal, M. A. S., Smith, B., Olson, S., Aikawa, J.-I., Kimata, K., & Esko, J. D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241175798 · Cited by 168
Solution Structures of Chemoenzymatically Synthesized Heparin and Its Precursors
Zhang, Z., McCallum, S. A., Xie, J., Nieto, L., Corzana, F., Jiménez-Barbero, J., Chen, M., Liu, J., & Linhardt, R. J. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8026345 · Cited by 168
Self-citationComparison of essential medicines lists in 137 countries
Persaud, N., Jiang, M., Shaikh, R., Bali, A., Oronsaye, E., Woods, H., Drozdzal, G., Rajakulasingam, Y., Maraj, D., Wadhawan, S., et al. (2019) · Bulletin of the World Health Organization · doi:10.2471/blt.18.222448 · Cited by 151
Porcine Respiratory and Reproductive Syndrome Virus Variants, Vietnam and China, 2007
Feng, Y., Zhao, T., Nguyen, T. T., Inui, K., Ma, Y., Nguyen, T. H., Nguyen, V. C., Liu, D., Bui, Q. A., To, T. L., et al. (2008) · Emerging infectious diseases · doi:10.3201/eid1411.071676 · Cited by 150
Merli, G. J., & Groce, J. B., III (2010) · PubMed · Cited by 146
E. coli K5 fermentation and the preparation of heparosan, a bioengineered heparin precursor
Wang, Z., Ly, M., Zhang, F., Zhong, W., Suen, A., Hickey, A. M., Dordick, J. S., & Linhardt, R. J. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22898 · Cited by 133
Self-citationFrom Farm to Pharma: An Overview of Industrial Heparin Manufacturing Methods
van der Meer, J., Kellenbach, E. R., & van den Bos, L. (2017) · Molecules · doi:10.3390/molecules22061025 · Cited by 133
Loganathan, D., Wang, H. M., Mallis, L. M., & Linhardt, R. J. (1990) · Biochemistry · doi:10.1021/bi00470a015 · Cited by 130
Self-citationGeneration of “Neoheparin” from E. coli K5 Capsular Polysaccharide
Lindahl, U., Li, J., Kusche‐Gullberg, M., Salmivirta, M., Alaranta, S., Veromaa, T., EMEIS, J. J., Roberts, I. S., Taylor, C. M., Oreste, P., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049812m · Cited by 124
Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent
Walenga, J. M., Jeske, W. P., Frapaise, F.-X., Bick, R. L., Fareed, J., & Samama, M. M. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.3.397 · Cited by 121
Biosynthesis of heparin. Substrate specificity of heparosan N-sulfate D-glucuronosyl 5-epimerase.
Jacobsson, I., Lindahl, U., Jensen, J. W., Rodén, L., Prihar, H. S., & FEINGOLD, D. S. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)43565-4 · Cited by 119
The US regulatory and pharmacopeia response to the global heparin contamination crisis
Szajek, A. Y., Chess, E. K., Johansen, K. B., Gratzl, G., Gray, E., Keire, D. A., Linhardt, R. J., Liu, J., Morris, T. S., Mulloy, B., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3606 · Cited by 117
Self-citationProcessing of Macromolecular Heparin by Heparanase
Gong, F., Jemth, P., Galvis, M. L. E., Vlodavsky, I., Horner, A., Lindahl, U., & Li, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300925200 · Cited by 94
Combinatorial one-pot chemoenzymatic synthesis of heparin
Bhaskar, U., Li, G.-Y., Fu, L., Onishi, A., Suflita, M., Dordick, J., & Linhardt, R. (2014) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2014.10.054 · Cited by 94
Self-citationPikas, D. S., Eriksson, I., & Kjellén, L. (2000) · Biochemistry · doi:10.1021/bi992524l · Cited by 83
Carlsson, P., & Kjellén, L. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-23056-1_2 · Cited by 78
Zhang, L., Lawrence, R., Schwartz, J. J., Bai, X., Wei, G., Esko, J. D., & ROSENBERG, R. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100204200 · Cited by 77
Scientific considerations in the review and approval of generic enoxaparin in the United States
Lee, S., Raw, A., Yu, L. X., Lionberger, R., Ya, N., Verthelyi, D., Rosenberg, A., Kozlowski, S., Webber, K., & Woodcock, J. (2013) · Nature Biotechnology · doi:10.1038/nbt.2528 · Cited by 74
Metabolic engineering of Chinese hamster ovary cells: Towards a bioengineered heparin
Baik, J. Y., Gasimli, L., Yang, B., Datta, P., Zhang, F., Glass, C. A., Esko, J. D., Linhardt, R. J., & Sharfstein, S. T. (2012) · Metabolic Engineering · doi:10.1016/j.ymben.2012.01.008 · Cited by 73
Self-citationEnhanced activity and stability of papain immobilized on CNBr-activated sepharose
Homaei, A. A. (2015) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2015.01.055 · Cited by 71
Synthesis of bioengineered heparin by recombinant yeast Pichia pastoris
Zhang, Y., Wang, Y., Zhou, Z., Wang, P., Xi, X., Hu, S., Xu, R., Du, G., Li, J., Chen, J., et al. (2022) · Green Chemistry · doi:10.1039/d1gc04672a · Cited by 65
Mauri, L., Boccardi, G., Torri, G., Karfunkle, M., Macchi, E., Muzi, L., Keire, D. A., & Guerrini, M. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.12.031 · Cited by 64
Molecular Mechanism of Substrate Specificity for Heparan Sulfate 2-O-Sulfotransferase
Liu, C., Sheng, J., Krahn, J. M., Perera, L., Xu, Y., Hsieh, P.-H., Dou, W., Liu, J., & Pedersen, L. C. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.530535 · Cited by 60
Chen, Y., Lin, L., Agyekum, I., Zhang, X., Ange, K. S., Yu, Y., Zhang, F., Liu, J., Amster, I. J., & Linhardt, R. J. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.11.023 · Cited by 57
Self-citationHagner-McWhirter, A. (2000) · Glycobiology · doi:10.1093/glycob/10.2.159 · Cited by 52
Préchoux, A., Halimi, C., Simorre, J., Lortat‐Jacob, H., & Laguri, C. (2015) · ACS Chemical Biology · doi:10.1021/cb501037a · Cited by 51
Anticoagulation strategies in extracorporeal circulatory devices in adult populations
Kato, C. M., Oakes, M., Kim, M., Desai, A., Olson, S. R., Raghunathan, V. M., & Shatzel, J. J. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13520 · Cited by 51
Use of biosynthetic enzymes in heparin and heparan sulfate synthesis
Chappell, E. P., & Liu, J. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.11.053 · Cited by 49
Analysis of Heparins Derived From Bovine Tissues and Comparison to Porcine Intestinal Heparins
Ange, K. S., Onishi, A., Fu, L., Sun, X., Lin, L., Mori, D., Zhang, F., Dordick, J. S., Fareed, J., Hoppensteadt, D., et al. (2016) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029616643822 · Cited by 49
Self-citationHeavy heparin: A stable isotope-enriched, chemoenzymatically-synthesized, poly-component drug
Cress, B. F., Bhaskar, U., Vaidyanathan, D., Williams, A. J., Cai, C., Liu, X.-Y., Fu, L., M‐Chari, V., Zhang, F.-M., Mousa, S., et al. (2019) · Angewandte Chemie · doi:10.1002/anie.201900768 · Cited by 42
Self-citationMuñoz, E., Xu, D., Avci, F., Kemp, M. M., Liu, J., & Linhardt, R. (2006) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2005.11.051 · Cited by 41
Self-citationLow molecular weight heparin prevention of post-operative deep vein thrombosis in vascular surgery.
Speziale, F., Verardi, S., Taurino, M., Nicolini, G., Rizzo, L., Fiorani, P., & Palazzini, E. (1988) · PubMed · Cited by 40
Taylor, S., Hogwood, J., Guo, W., Yates, E. A., & Turnbull, J. E. (2019) · Scientific Reports · doi:10.1038/s41598-019-39093-6 · Cited by 40
Response surface optimization of the heparosan N-deacetylation in producing bioengineered heparin
Wang, Z., Li, J., Cheong, S., Bhaskar, U., Onishi, A., Zhang, F., Dordick, J. S., & Linhardt, R. J. (2011) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2011.08.013 · Cited by 38
Self-citationStable heparin-producing cell lines derived from the Furth murine mastocytoma.
Montgomery, R. I., Lidholt, K., Flay, N., Liang, J., Vertel, B. M., Lindahl, U., & Esko, J. D. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.23.11327 · Cited by 36
Tovar, A. M. F., Capillé, N. V., dos Santos, G. R. C., Vairo, B. C., Oliveira, S.-N., Fonseca, R. J. C., & Mourão, P. A. S. (2012) · Thrombosis and Haemostasis · doi:10.1160/th-11-07-0518 · Cited by 36
Al-Hakim, A. H. (2021) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296211052293 · Cited by 35
Running thin: implications of a heparin shortage
McCarthy, C. P., Vaduganathan, M., Solomon, E. J., Sakhuja, R., Piazza, G., Bhatt, D. L., Connors, J. M., & Patel, N. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33135-6 · Cited by 30
Bioengineered human heparin with anticoagulant activity
Lord, M. S., Cheng, B., Tang, F., Lyons, J. G., Rnjak‐Kovacina, J., & Whitelock, J. M. (2016) · Metabolic Engineering · doi:10.1016/j.ymben.2016.07.006 · Cited by 29
Mauri, L., Marinozzi, M. R., Phatak, N. L., Karfunkle, M., Ange, K. S., Guerrini, M., Keire, D. A., & Linhardt, R. J. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00142 · Cited by 29
Self-citationColombo, E., Mauri, L., Marinozzi, M. R., Rudd, T. R., Yates, E. A., Ballabio, D., & Guerrini, M. (2022) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2022.114724 · Cited by 27
Zhang, J., Suflita, M., Li, G., Zhong, W., Li, L., Dordick, J. S., Linhardt, R. J., & Zhang, F. (2015) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-014-1466-1 · Cited by 23
Self-citationBovine Mucosal Heparins Are Comparable to Porcine Mucosal Heparin at USP Potency Adjusted Levels
Jeske, W. P., Kouta, A., Farooqui, A., Siddiqui, F., Rangnekar, V., Niverthi, M., Laddu, R., Hoppensteadt, D., Iqbal, O., Walenga, J. M., et al. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2018.00360 · Cited by 23
Heparinization for Routine Hemodialysis
Ward, R. A. (1995) · Advances in Renal Replacement Therapy · doi:10.1016/s1073-4449(12)80034-3 · Cited by 22
Zhang, J., Suflita, M., Fiaschetti, C. M., Li, G., Li, L., Zhang, F., Dordick, J. S., & Linhardt, R. J. (2014) · Journal of Applied Microbiology · doi:10.1111/jam.12684 · Cited by 22
Self-citationVilanova, E., Vairo, B. C., Oliveira, S.-N. M. C. G., Glauser, B. F., Capillé, N. V., dos Santos, G. R. C., Tovar, A. M. F., Pereira, M. S., & Mourão, P. A. S. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00016 · Cited by 22
Yan, L., Fu, L., Xia, K., Chen, S., Zhang, F., Dordick, J. S., & Linhardt, R. J. (2020) · Biomolecules · doi:10.3390/biom10111516 · Cited by 21
Self-citationStructural Determinants of Substrate Recognition and Catalysis by Heparan Sulfate Sulfotransferases
Gesteira, T. F., Marforio, T. D., Mueller, J. W., Calvaresi, M., & Coulson‐Thomas, V. J. (2021) · ACS Catalysis · doi:10.1021/acscatal.1c03088 · Cited by 20
Chemobiocatalytic Synthesis of a Low-Molecular-Weight Heparin
Yu, Y., Fu, L., He, P., Xia, K., Varghese, S., Wang, H., Zhang, F., Dordick, J. S., & Linhardt, R. J. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00928 · Cited by 20
Self-citationDownstream Products are Potent Inhibitors of the Heparan Sulfate 2-O-Sulfotransferase
Thieker, D. F., Xu, Y., Chapla, D. G., Nora, C., Qiu, H. Y., Felix, T. W., Wang, L., Moremen, K. W., Liu, J., Esko, J. D., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-29602-4 · Cited by 19
Preparation of Low Molecular Weight Heparin from a Remodeled Bovine Intestinal Heparin
Baytaş, S. N., Varghese, S., Jin, W., Yu, Y., He, P., Douaisi, M. P., Zhang, F., Brodfuehrer, P. R., Xia, K., Dordick, J. S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02019 · Cited by 16
Self-citationBioengineering murine mastocytoma cells to produce anticoagulant heparin
Gasimli, L., Glass, C. A., Datta, P. K., Yang, B., Li, G., Gemmill, T. R., Baik, J. Y., Sharfstein, S. T., Esko, J. D., & Linhardt, R. J. (2013) · Glycobiology · doi:10.1093/glycob/cwt108 · Cited by 15
Self-citationInvestigation of the heparin–thrombin interaction by dynamic force spectroscopy
Wang, C., Ying-zi, J., Desai, U. R., & Yadavalli, V. K. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.01.016 · Cited by 12
Higashi, N., Waki, M., Sue, M., Kogane, Y., Shida, H., Tsunekawa, N., Hasan, A., Sato, T. A., Kitahara, A., Kasaoka, T., et al. (2013) · Biochemical Journal · doi:10.1042/bj20131463 · Cited by 11
Risk of transmission of BSE via drugs of bovine origin
Verdrager, J. (1999) · The Lancet · doi:10.1016/s0140-6736(05)76082-7 · Cited by 7
Polysaccharide Sequence Influences the Specificity and Catalytic Activity of Glucuronyl C5-Epimerase
Vaidyanathan, D., Xia, K., Yu, Y., Linhardt, R. J., & Dordick, J. S. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00419 · Cited by 3
Self-citation
Cited by
Fetal bovine serum: how to leave it behind in the pursuit of more reliable science
Weber, T., Malakpour‐Permlid, A., Chary, A., D’Alessandro, V., Haut, L., Seufert, S., Wenzel, E. V., Hickman, J. J., Bieback, K., Wiest, J., et al. (2025) · Frontiers in Toxicology · doi:10.3389/ftox.2025.1612903 · Cited by 53
Surface biofunctionalised porous materials: advances, challenges, and future prospects
Zhang, A., Wong, K. U., Xia, Y., Bilek, M., Yeo, G. C., & Akhavan, B. (2025) · Progress in Materials Science · doi:10.1016/j.pmatsci.2025.101518 · Cited by 32
Multifaceted Heparin: Diverse Applications beyond Anticoagulant Therapy
Sultana, R., & Kamihira, M. (2024) · Pharmaceuticals · doi:10.3390/ph17101362 · Cited by 20
Quality control, safety assessment and preparation approaches of low molecular weight heparin
Yu, Y., Song, Y., Zhao, Y., Wang, N., Wei, B., Linhardt, R. J., Dordick, J. S., Zhang, F., & Wang, H. (2024) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2024.122216 · Cited by 20
Self-citationBioengineered heparin: Advances in production technology
Sultana, R., & Kamihira, M. (2024) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108456 · Cited by 20
Metadata
- Authors
- Douaisi, M., Paskaleva, E. E., Fu, L., Grover, N., McManaman, C. L., Varghese, S., Brodfuehrer, P. R., Gibson, J. M., de Joode, I., Xia, K., Brier, M. I., Simmons, T. J., Datta, P., Zhang, F., Onishi, A., Hirakane, M., Mori, D., Linhardt, R. J., & Dordick, J. S.
- Affiliations
- Rensselaer Polytechnic Institute (US)
- Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180
- Corresponding author
- Linhardt, Robert J.
- Dordick, Jonathan S.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2024-03-18
- Volume
- 121
- Issue
- 14
- Pages
- e2315586121-e2315586121
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC10998570
- OpenAlex
- W4392931669
- Cited by
- 31
- References
- 69
- Citations by year
- 2026: 13 · 2025: 13 · 2024: 5
- FWCI
- 6.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Heparin Applied Research Center (NA)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Life Sciences › Agricultural and Biological Sciences › Food Science › Polysaccharides Composition and Applications
- Keywords
- heparin, low molecular weight heparin, enoxaparin, chemoenzymatic synthesis, immobilized enzymes
- MeSH terms
- Animals, Anticoagulants, Drug Contamination, Heparin, Heparin, Low-Molecular-Weight, Molecular Weight, Swine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.